22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ATEA PHARMACEUTICALS INC. › 2024-2025

ATEA PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ATEA PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 119Asset managers, any item
  • 777Fund votes
  • June 20, 2025Meeting date

Results at a glance

Meeting of June 20, 2025: 5 items on ATEA PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2025: 5 passed (calculated).

Dissent

Significant dissent: 3 directors (30.4%, 21.3%, 21.2% against).

Notable dissent: 1 say-on-pay vote (79.3% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: BML Capital (13F, 8.4%, as of September 30, 2026)

Explore ATEA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ATEA PHARMACEUTICALS INC.

These tallies are ATEA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ATEA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 20, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Bruno Lucidi 46,640,587---- 12,559,08415,781,736 79%Passed (calculated)—
Elect Director: Polly Murphy, DVM, PhD 41,184,263---- 18,015,40815,781,736 70%Passed (calculated)—
Elect Director: Bruce Polsky, MD, MACP, FIDSA 46,597,653---- 12,602,01815,781,736 79%Passed (calculated)—
2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 73,766,2741,192,65922,474 --0 98%Passed (calculated)—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers 46,450,30212,107,029642,340 --15,781,736 79%Passed (calculated)—

Source: ATEA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 20, 2025 — read the filing on EDGAR.

How asset managers voted at the ATEA PHARMACEUTICALS INC. 2024-2025 meeting

119 asset managers disclosed a vote on at least one ATEA PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Bruce Polsky, MD, MACP, FIDSA

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 46,597,653WITHHELD: 12,602,018
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class II Directors: Bruce Polsky, MD, MACP, FIDSA

ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bruce Polsky, MD, MACP, FIDSA”): 46,597,653 for, 12,602,018 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 15,155,741 for, 137,333 withheld, 11,984 abstained.

FOR
FOR: 15,155,741ABSTAIN: 11,984WITHHOLD: 137,333
Largest asset managers voting on “Election of Class II Directors: Bruce Polsky, MD, MACP, FIDSA” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,765,5680 00For
Fidelity3,982,9870 00For
BlackRock3,647,0180 00For
Charles Schwab621,1550 00For
JPMorgan288,7140 00For
Equitable138,7930 0119,220Mixed
TIAA254,2490 00For
American Century163,0930 00For
BRIDGEWAY FUNDS INC133,3000 00For
QUANTITATIVE MASTER SERIES LLC132,5460 00For
Goldman Sachs131,5370 00For
AIG/SunAmerica96,0170 00For
Lincoln Financial78,6500 04,025For
MASTER INVESTMENT PORTFOLIO70,3250 00For
Delaware/Macquarie70,0000 00For
Brighthouse65,5140 00For
Nationwide64,4790 00For
T. Rowe Price50,6560 00For
Global X46,2920 00For
Voya44,4860 00For
Northern Trust40,8170 00For
Pacific Life39,2270 00For
Bridge Builder Trust36,1830 00For
Invesco34,5100 00For
Columbia Threadneedle33,2010 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Bruno Lucidi

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 46,640,587WITHHELD: 12,559,084
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class II Directors: Bruno Lucidi

ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bruno Lucidi”): 46,640,587 for, 12,559,084 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 15,155,741 for, 137,333 withheld, 11,984 abstained.

FOR
FOR: 15,155,741ABSTAIN: 11,984WITHHOLD: 137,333
Largest asset managers voting on “Election of Class II Directors: Bruno Lucidi” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,765,5680 00For
Fidelity3,982,9870 00For
BlackRock3,647,0180 00For
Charles Schwab621,1550 00For
JPMorgan288,7140 00For
Equitable138,7930 0119,220Mixed
TIAA254,2490 00For
American Century163,0930 00For
BRIDGEWAY FUNDS INC133,3000 00For
QUANTITATIVE MASTER SERIES LLC132,5460 00For
Goldman Sachs131,5370 00For
AIG/SunAmerica96,0170 00For
Lincoln Financial78,6500 04,025For
MASTER INVESTMENT PORTFOLIO70,3250 00For
Delaware/Macquarie70,0000 00For
Brighthouse65,5140 00For
Nationwide64,4790 00For
T. Rowe Price50,6560 00For
Global X46,2920 00For
Voya44,4860 00For
Northern Trust40,8170 00For
Pacific Life39,2270 00For
Bridge Builder Trust36,1830 00For
Invesco34,5100 00For
Columbia Threadneedle33,2010 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Polly Murphy, DVM, PhD

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD
FOR: 41,184,263WITHHELD: 18,015,408
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class II Directors: Polly Murphy, DVM, PhD

ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Polly Murphy, DVM, PhD”): 41,184,263 for, 18,015,408 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 14,180,450 for, 1,075,524 withheld, 49,084 abstained.

FOR
FOR: 14,180,450ABSTAIN: 49,084WITHHOLD: 1,075,524
Largest asset managers voting on “Election of Class II Directors: Polly Murphy, DVM, PhD” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,765,5680 00For
Fidelity3,979,4980 03,489For
BlackRock3,647,0180 00For
Charles Schwab621,1550 00For
JPMorgan288,7140 00For
Equitable138,7930 0119,220Mixed
TIAA254,2490 00For
American Century00 0163,093Withhold
BRIDGEWAY FUNDS INC00 0133,300Withhold
QUANTITATIVE MASTER SERIES LLC132,5460 00For
Goldman Sachs00 0131,537Withhold
AIG/SunAmerica00 096,017Withhold
Lincoln Financial78,6500 04,025For
MASTER INVESTMENT PORTFOLIO70,3250 00For
Delaware/Macquarie00 070,000Withhold
Brighthouse42,4290 023,085Mixed
Nationwide21,6080 042,871Mixed
T. Rowe Price50,6560 00For
Global X00 046,292Withhold
Voya00 044,486Withhold
Northern Trust00 040,817Withhold
Pacific Life39,2270 00For
Bridge Builder Trust36,1830 00For
Invesco00 034,510Withhold
Columbia Threadneedle00 033,201Withhold

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 8 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST
FOR: 46,450,302AGAINST: 12,107,029
Details: description as filed, official tally, votes by 119 asset managers

Description as filed by funds: APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY.

ATEA PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 46,450,302 for, 12,107,029 against, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 43 asset managers voting on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPA” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,765,5680 00For
Fidelity3,982,9870 00For
BlackRock3,647,0180 00For
Charles Schwab621,1550 00For
JPMorgan0288,714 00Against
Equitable258,0130 00For
TIAA254,2490 00For
American Century0163,093 00Against
BRIDGEWAY FUNDS INC0133,300 00Against
QUANTITATIVE MASTER SERIES LLC132,5460 00For
Goldman Sachs131,5370 00For
AIG/SunAmerica96,0170 00For
Lincoln Financial61,62521,050 00Mixed
MASTER INVESTMENT PORTFOLIO70,3250 00For
Delaware/Macquarie70,0000 00For
Brighthouse23,08542,429 00Mixed
Nationwide64,4790 00For
T. Rowe Price50,6560 00For
Global X46,2920 00For
Voya44,4860 00For
Northern Trust40,8170 00For
Pacific Life39,2270 00For
Bridge Builder Trust36,1830 00For
Invesco34,5100 00For
Columbia Threadneedle33,2010 00For

Fund voting reports, all 43 managers: 14,652,211 for, 656,100 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 91 asset managers voting on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPA” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity6,015,4770 00For
BlackRock3,315,373671 00For
Bain Capital Life Sciences Investors, LLC2,485,6380 00For
GEODE CAPITAL MANAGEMENT, LLC1,932,3500 00For
State Street1,406,7103,213 00For
Renaissance1,053,6790 00For
Charles Schwab621,3030 00For
Newtyn Management, LLC580,0000 00For
JPMorgan0565,076 00Against
Northern Trust432,9500 00For
Two Sigma423,8580 00For
Nuveen255,8470 00For
DE Shaw255,5540 00For
MELLON INVESTMENTS Corp237,8000 00For
Wellington221,6940 00For
American Century0163,093 00Against
Dimensional156,2810 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC147,1370 00For
BRIDGEWAY CAPITAL MANAGEMENT, LLC0143,100 00Against
AllianceBernstein119,2200 00For
Point72116,7340 00For
STRS OHIO105,5000 00For
Maryland State Retirement & Pension System94,4450 00For
STATE OF WISCONSIN INVESTMENT BOARD93,8000 00For
Vanguard89,0810 00For

Institutional-manager reports, all 91 managers: 20,920,139 for, 1,033,891 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 73,766,274AGAINST: 1,192,659
Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

ATEA PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 73,766,274 for, 1,192,659 against, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 15,308,311 for.

FOR
FOR: 15,308,311
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCA” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,765,5680 00For
Fidelity3,982,9870 00For
BlackRock3,647,0180 00For
Charles Schwab621,1550 00For
JPMorgan288,7140 00For
Equitable258,0130 00For
TIAA254,2490 00For
American Century163,0930 00For
BRIDGEWAY FUNDS INC133,3000 00For
QUANTITATIVE MASTER SERIES LLC132,5460 00For
Goldman Sachs131,5370 00For
AIG/SunAmerica96,0170 00For
Lincoln Financial82,6750 00For
MASTER INVESTMENT PORTFOLIO70,3250 00For
Delaware/Macquarie70,0000 00For
Brighthouse65,5140 00For
Nationwide64,4790 00For
T. Rowe Price50,6560 00For
Global X46,2920 00For
Voya44,4860 00For
Northern Trust40,8170 00For
Pacific Life39,2270 00For
Bridge Builder Trust36,1830 00For
Invesco34,5100 00For
Columbia Threadneedle33,2010 00For

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

Largest ATEA PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 85,579,475 shares outstanding at the time of that meeting.

Fund voting reports: top ATEA PHARMACEUTICALS INC. shareholders by shares voted on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 5.57%
2Fidelity 4.65%
3BlackRock 4.26%
4Charles Schwab 0.73%
5JPMorgan 0.34%
6Equitable 0.30%
7TIAA 0.30%
8American Century 0.19%
9BRIDGEWAY FUNDS INC 0.16%
10QUANTITATIVE MASTER SERIES LLC 0.15%
Institutional-manager reports: top ATEA PHARMACEUTICALS INC. shareholders by shares voted on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 7.03%
2BlackRock 3.87%
3Bain Capital Life Sciences Investors, LLC 2.90%
4GEODE CAPITAL MANAGEMENT, LLC 2.26%
5State Street 1.65%
6Renaissance 1.23%
7Charles Schwab 0.73%
8Newtyn Management, LLC 0.68%
9JPMorgan 0.66%
10Northern Trust 0.51%

Reported ATEA PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ATEA PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock8,943,065 10.45%Form 13F, quarter ended March 31, 2025
Jean-Pierre Sommadossi8,876,453 10.37%Schedule 13G, filed May 14, 2025
BML Investment Partners, L.P.7,490,000 8.75%Schedule 13G, filed February 9, 2026
FMR LLC6,618,297 7.73%Proxy statement (DEF 14A), proxy filed April 29, 2025
FMR (Fidelity)6,018,019 7.03%Form 13F, quarter ended March 31, 2025
JPM Partners LLC5,866,025 6.85%Proxy statement (DEF 14A), proxy filed April 29, 2025
Vanguard Group4,727,702 5.52%Form 13F, quarter ended March 31, 2025
Radoff Bradley Louis3,380,100 3.95%Schedule 13D, filed April 17, 2025
Geode Capital1,977,337 2.31%Form 13F, quarter ended March 31, 2025
State Street1,770,688 2.07%Form 13F, quarter ended March 31, 2025

Percentages above are of 85,579,475 shares outstanding, as reported by ATEA PHARMACEUTICALS INC. on its Form 10-Q dated May 9, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ATEA PHARMACEUTICALS INC.'s shareholder meeting held June 20, 2025, in the 2024-2025 proxy season, 119 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 777 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE… — FOR was 79% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ATEA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ATEA PHARMACEUTICALS INC.’s 10-Q dated May 9, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ATEA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “ATEA PHARMACEUTICALS (AVIR) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/atea-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.